drug · protein
efinopegdutide
Phase 2updated 3mo agoby $MRK Merck & Co., Inc.🔗 ChEMBL
Phase 2community read0 votes
Protein drug with a maximum clinical stage of Phase 2 (across all indications), with 5 investigational indications.
targets
Glucagon receptorGlucagon-like peptide 1 receptor
all catalysts(0)
nothing on the calendar yet
Trials studying efinopegdutide
- phase2A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)
- phase2A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)
- phase1A Study of Efinopegdutide in Participants With Hepatic Impairment (MK-6024-014)
- phase2Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (MK-6024-016)
- phase1A Study of Efinopegdutide in Healthy Obese Participants (MK-6024-015)
- phase1A Clinical Study of Efinopegdutide (MK-6024) in Healthy Chinese Volunteers (MK-6024-011)
- phase2A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001)
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that